Antibodies for treatment of cancer expressing claudin 6

US10233253B2 · kind B2 · utility

Assignees

• Ganymed Pharmaceuticals GmbH · DE
• Johannes Gutenberg-Universität Mainz · DE

Inventors

• Ugur Sahin · Mainz, DE
• Ozlem Tureci · Homburg, DE
• Michael Koslowski · Mainz, DE
• Korden Walter · Mainz, DE
• Stefan Woll · Stadecken-Elsheim, DE
• Maria Kreuzberg · Mainz, DE
• Bernd Hubner · Munich, DE
• Michael Erdeljan · Mainz, DE
• Michael Weichel · Bischofsheim, DE

Key dates

• Filing date: Mar 21, 2016
• Grant date: Mar 19, 2019
• Expiry date: Mar 21, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLDN6, including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.